Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It works by increasing incretin hormone levels, which stimulates insulin release and reduces glucagon secretion in a glucose-dependent manner. Unlike other DPP-4 inhibitors, linagliptin has primarily non-renal elimination, making it suitable for patients with renal impairment.
Mechanism of Action
Linagliptin is a competitive, reversible dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels (GLP-1 and GIP) by inhibiting their degradation. This enhances glucose-dependent insulin secretion and decreases glucagon secretion from pancreatic alpha cells, resulting in reduced hepatic glucose production.
Indications
- Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Common Doses
- 5 mg
Dosage
The recommended dose of linagliptin is 5 mg once daily, taken with or without food. When used in combination with other antidiabetic agents, dosage adjustments may be necessary to minimize hypoglycemia risk.
Contraindications
- History of serious hypersensitivity reaction to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions)
- Patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis
Side Effects
- Common: Nasopharyngitis, headache, upper respiratory tract infection
- Serious: Pancreatitis, hypersensitivity reactions (anaphylaxis, angioedema), severe arthralgia, bullous pemphigoid
Interactions
- Strong P-glycoprotein or CYP3A4 inducers (e.g., rifampin): May significantly decrease linagliptin exposure; consider alternative treatments
- Insulin or insulin secretagogues: May increase risk of hypoglycemia; dosage reduction of these agents may be required
Counseling Points
- Take once daily with or without food
- Do not use for type 1 diabetes or diabetic ketoacidosis
- Report symptoms of pancreatitis (severe abdominal pain with or without vomiting)
- Report signs of allergic reaction (rash, hives, swelling of face/lips/tongue/throat)
- Monitor blood glucose regularly as directed by healthcare provider
- Continue diet and exercise program